Q BioMed (QBIO) Stock Price, News & Analysis

Company Overview

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 55,114 shs
• Market Capitalization: $9,000.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QBIO Stock Analysis - Frequently Asked Questions

How were Q BioMed's earnings last quarter?

Q BioMed Inc. (OTCMKTS:QBIO) announced its earnings results on Wednesday, July, 14th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The business earned $0.05 million during the quarter.

How do I buy shares of Q BioMed?

Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Q BioMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Q BioMed investors own include Intel (INTC), Washington Trust Bancorp (WASH), Cisco Systems (CSCO), Nokia Oyj (NOK), NVIDIA (NVDA), Micron Technology (MU) and NewAge (NBEV).

Company Calendar

• Last Earnings: 7/14/2021
• Today: 5/10/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:QBIO
• Previous Symbol: NASDAQ:QBIO
• CIK: 1596062
• Web: www.qbiomed.com
• Phone: (646) 889-2226
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $280,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 91,970,000
• Free Float: 104,178,000
• Market Cap: $9,000.00
• Optionable: Not Optionable
• Beta: 2.22